肿瘤标记物联合检测在非小细胞肺癌化疗中的意义

THE SIGNIFICANCE OF COMBINED DETECTION OF TUMOR MARKERS IN CHEMOTHERAPY OF NON-SMALL CELL LUNG CANCER

目的探讨联合检测肿瘤标记物CEA、CA125、CA19-9、CA50对于非小细胞肺癌化疗的意义。方法对60例非小细胞肺癌病人行4个疗程化疗，化疗方案为NP、TP或GP，监测第1次化疗前和第3次化疗前肿瘤标记物CEA、CA125、CA19-9、CA50水平的变化，并根据化疗前后肺部CT改变进行分析。结果第3次化疗前，非小细胞肺癌病人CEA、CA125、CA50水平较第1次化疗前下降，差异有显著意义（t=2．367～3．125，P〈0．05、0．01）。化疗有效病人第3次化疗前CEA、CA125、CAS0水平低于第1次化疗前，差异有显著意义（t=2．123～3．089，P〈0．05、0．01）。结论监测肿瘤标记物CEA、CA125、CA50水平的变化有助于非小细胞肺癌化疗后疗效的判断。

Objective To assess the value of combined detection of tumor markers CEA,CA125,CA19-9 and CA50 in chemotherapy of non-small cell lung cancer （NSCLC）. Methods Sixty NSCLC patients were given four courses of chemotherapy, the regimen was NP, TP or GP. The tumor markers were detected before the first and the third treatment, the changes of the markers were analyzed based on the changes of the lung on CT. Results Before the third chemotherapy, for those who responed well to the therapy, the CEA, CA125 and CA50 declined compared with before the first chemotherapy （t = 2. 367- 3. 125, P〈 0.05,0.01）. Conclusion The detection of CEA,CA125 and CA50 is conducive to the judgement of the efficacy of chemotherapy for non-small cell lung cancer.